Signant Health Appoints Clinical Research Expert as Vice President

Dr. Graham C. Ellis joins the company to strengthen metabolic disease and diabetes trial capabilities.

Apr. 2, 2026 at 1:07pm

Got story updates? Submit your updates here. ›

Signant Health, a leader in evidence generation for clinical trials, has announced the appointment of Dr. Graham C. Ellis as their new Clinical Vice President. Dr. Ellis brings over 25 years of experience as a specialist physician and clinical research expert, and will focus on strengthening the company's capabilities in metabolic disease and diabetes trials.

Why it matters

Signant Health's ability to generate high-quality scientific evidence is crucial for improving patient outcomes in clinical trials, especially in complex therapeutic areas like metabolic diseases and diabetes. Dr. Ellis's deep expertise in these fields will help the company enhance its services and support more effective drug development.

The details

In his new role, Dr. Ellis will leverage his extensive background in clinical medicine and drug development to support Signant Health's work in metabolic disease and diabetes trials. His appointment is intended to bolster the company's capabilities in these important therapeutic areas.

  • Dr. Ellis was appointed as Signant Health's Clinical Vice President on April 2, 2026.

The players

Signant Health

A leader in evidence generation for modern clinical trials.

Dr. Graham C. Ellis

A specialist physician and clinical research expert with over 25 years of experience, who has been appointed as Signant Health's new Clinical Vice President.

Got photos? Submit your photos here. ›

What they’re saying

“I have spent my career at the intersection of clinical medicine and drug development, where the quality of scientific evidence directly shapes patient outcomes.”

— Dr. Graham C. Ellis, Clinical Vice President

The takeaway

Signant Health's appointment of Dr. Graham C. Ellis as Clinical Vice President demonstrates the company's commitment to strengthening its capabilities in critical therapeutic areas like metabolic disease and diabetes, which will ultimately help improve patient outcomes through more effective clinical trials.